Amide-to-ester substitution as a strategy for optimizing PROTAC permeability and cellular activity. Great work by Adam, Conner, and Tori Klein from Scott Lokey’s lab. Read the pre-print article. Authors: Klein, V.G., Bond, A.G, Craigon, C., Lokey, R.S., Ciulli, A.* Title:…
A new translational research centre will bolster the University of Dundee’s world-leading position in a field that is revolutionising drug discovery, while helping to facilitate the development of high growth companies and create skilled jobs. A new translational research centre…
Will and Manfred’s review on the present and future of PROTACs for cancer therapy is now out in Current Opinion in Pharmacology Read the full article. Authors: William Farnaby*, Manfred Koegl*, Darryl B. McConnell, Alessio Ciulli Title: Transforming targeted cancer…
Amphista Therapeutics, a University of Dundee spinout company, has announced a near-£40 million investment that will further its work to develop new drugs for a range of diseases. Amphista is a biopharmaceutical company creating first-in-class therapeutics that harness the body’s…
Amphista Therapeutics, the spin out company from the lab of Professor Alessio Ciulli, was awarded the ‘Financing Deal of the Year’ award 2021 at the Scrip Awards last month. This was in recognition of their $53M Series B funding. The…